Algorized Raises $4.3 Million in Seed Funding to Drive Innovation in People-Sensing Technology for Safe Human-Machine Interaction 8-11-2024, 00:07

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Smith+Nephew steps forward with innovative Sports Medicine foot & ankle repair solutions in Australia and New Zealand 17-02-2025, 06:00